Low density lipoprotein subfractions systematic review of measurement methods and association with cardiovascular outcomes

In December 2006 the Food and Drug Administration (FDA) held a public hearing on lipoprotein subfractions (www.fda.gov/OHRMS/DOCKETS/ac/06/transcripts/2006-4263t1-01t.pdf, accessed Feb 19, 2008). Several questions were formulated from this meeting regarding the use of low density lipoprotein (LDL) (...

Full description

Main Authors: Balk, Ethan, Ip, Stanley (Author), Chung, Mei (Author), Lau, Joseph (Author)
Corporate Authors: United States Agency for Healthcare Research and Quality, Tufts Evidence-based Practice Center, Technology Assessment Program (Agency for Healthcare Research and Quality)
Format: eBook
Language:English
Published: Rockville, Maryland Agency for Healthcare Research and Quality June 16, 2008, 2008
Series:Technology assessment report
Subjects:
Online Access:
Collection: National Center for Biotechnology Information - Collection details see MPG.ReNa
Summary:In December 2006 the Food and Drug Administration (FDA) held a public hearing on lipoprotein subfractions (www.fda.gov/OHRMS/DOCKETS/ac/06/transcripts/2006-4263t1-01t.pdf, accessed Feb 19, 2008). Several questions were formulated from this meeting regarding the use of low density lipoprotein (LDL) (and high density lipoprotein (HDL)) subfractions for clinical decision making. Based on this hearing, the Centers for Medicare & Medicaid Services (CMS) requested a review of the literature on LDL subfractions and the risk of cardiovascular heart disease (CVD). After an early overview of the potentially relevant literature by the Tufts Evidence-based Practice Center (Tufts EPC), the questions of interest for this report were restricted to a description of the measurement methods that potentially could be routinely used by clinical laboratories, comparisons of the different measurement methods, a review of the evidence regarding the association between LDL subfractions and CVD, and a review of studies that evaluated an intervention that may "improve" LDL subfraction profiles and also evaluated cardiovascular outcomes. The primary population of interest for this review is the over age 65 Medicare population; however, data from all adults are also of interest to CMS.
Item Description:Title from PDF title page
Physical Description:1 PDF file (129 pages) illustrations